Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer-Reference-Cited by-同舟云学术

Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer

Published:2024-08-20 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Wiseman Charles L.¹,Holmes Jarrod P.²,Calfa Carmen³,Dakhil Shaker R.⁴,Bhattacharya Saveri⁵,Peoples George E.⁶,Lacher Markus D.¹^ORCID,Lopez-Lago Miguel¹,Kharazi Alex¹⁷,Del Priore Giuseppe¹⁸,Chang Mingjin¹,Adams Daniel L.⁹^ORCID,Williams William V.¹^ORCID

Affiliation:

1. Development, BriaCell Therapeutics Corp, Philadelphia, PA, USA

2. Hematology Oncology, Providence Medical Group Santa Rosa - Cancer Center, Santa Rosa, CA, USA

3. Medical Oncology, University of Miami, Miami, FL, USA

4. Medical Oncology, Cancer Center of Kansas, Wichita, KS, USA

5. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

6. Oncology, Lumabridge, San Antonio, TX, USA

7. Discovery, Stemedica Cell Technologies, Inc, San Diego, USA

8. Obstetrics & Gynecology, Morehouse School of Medicine, Atlanta, GA, USA

9. Discovery, Creatv MicroTech, Inc., Rockville, MD, USA

Funder

BriaCell Therapeutics Corp